BBVA USA Bancshares Inc. Raises Stock Holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

BBVA USA Bancshares Inc. increased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,478 shares of the biopharmaceutical company’s stock after acquiring an additional 160 shares during the period. BBVA USA Bancshares Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,571,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Mason Street Advisors LLC grew its position in Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. Mason Street Advisors LLC now owns 11,384 shares of the biopharmaceutical company’s stock worth $3,158,000 after purchasing an additional 168 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its position in shares of Regeneron Pharmaceuticals by 2,924.0% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 756 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 731 shares during the period. Sector Gamma AS grew its position in shares of Regeneron Pharmaceuticals by 31.6% during the 3rd quarter. Sector Gamma AS now owns 75,835 shares of the biopharmaceutical company’s stock valued at $21,037,000 after acquiring an additional 18,200 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI grew its position in shares of Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 19,520 shares of the biopharmaceutical company’s stock valued at $5,415,000 after acquiring an additional 672 shares during the period. Finally, Daiwa Securities Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 26.1% during the 3rd quarter. Daiwa Securities Group Inc. now owns 9,098 shares of the biopharmaceutical company’s stock valued at $2,523,000 after acquiring an additional 1,881 shares during the period. Institutional investors own 66.48% of the company’s stock.

In related news, Chairman P Roy Vagelos sold 22,149 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $363.83, for a total transaction of $8,058,470.67. Also, major shareholder Sanofi sold 172,904 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. Insiders have sold a total of 213,923 shares of company stock worth $63,262,696 in the last ninety days. Insiders own 11.84% of the company’s stock.

A number of research analysts have recently weighed in on the stock. Evercore ISI reissued a “buy” rating and set a $395.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, November 11th. JPMorgan Chase & Co. restated a “hold” rating and set a $375.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 6th. Credit Suisse Group upped their price target on shares of Regeneron Pharmaceuticals from $310.00 to $340.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, November 27th. Finally, Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $384.74.

Shares of REGN stock traded up $1.16 on Wednesday, hitting $369.97. 604,974 shares of the company’s stock traded hands, compared to its average volume of 775,807. The stock has a market capitalization of $40.51 billion, a price-to-earnings ratio of 18.69, a P/E/G ratio of 1.62 and a beta of 1.19. Regeneron Pharmaceuticals Inc has a one year low of $271.37 and a one year high of $442.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.27 and a current ratio of 4.03. The company’s fifty day simple moving average is $332.96 and its 200 day simple moving average is $307.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $1.54. The business had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.98 billion. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The company’s revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the firm earned $5.87 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.62 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals declared that its Board of Directors has initiated a share repurchase plan on Tuesday, November 5th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the biopharmaceutical company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Dividend Stocks – Are They Right For You?

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.